• HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • HOME
  • Pipeline
  • Clinical Focus
  • Technology
  • Team
  • News
  • About
  • canstockphoto6244971

    Febrile neutropenia is a common,
    life-threatening
    complication of chemotherapy

  • canstockphoto62820667

    Gut barrier Injury and Neutrophil
    depletion puts patients at risk for
    bacteremia and sepsis

  • canstockphoto7427952

    AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
    BACTERAEMIA BY STRENGTHENING
    INNATE GUT BARRIER DEFENSES

  • N1WT6iuIb

    eliminating the need for prophylactiC antibiotics

  • V1fz3suL-

    reducing risk of serious adverse events,
    antimicrobial resistance and
    microbiome dysbiosis

  • HOME
  • News
  • Lancet: AMR leading cause of death worldwide

Lancet: AMR leading cause of death worldwide

Antimicrobial Resistance estimated death toll 1,29 million in 2019

January 21, 2022
A comprehensive analysis of global impact of antimicrobial resistance (AMR) in 2019 estimates resistance itself caused 1.27 million deaths, and that antimicrobial-resistant infections played a role in 4.95 million deaths. Estimates for 204 countries and territories confirm AMR as a global health threat, with worst impacts in low- and middle-income countries (LMICs), though higher income countries also face alarmingly high levels of AMR.

Rapid investment in new treatments, improved infection control measures, and optimised use of antibiotics are among the measures that can help countries protect their health systems against the threat of AMR.

The analysis of 204 countries and territories, published in The Lancet, reveals that AMR is now a leading cause of death worldwide, higher than HIV/AIDS or malaria. It shows that many hundreds of thousands of deaths now occur due to common, previously treatable infections – such as lower respiratory and bloodstream infections – because the bacteria that cause them have become resistant to treatment. The report highlights an urgent need to scale up action to combat AMR, and outlines immediate actions for policymakers that will help save lives and protect health systems. These include optimising the use of existing antibiotics, taking greater action to monitor and control infections, and providing more funding to develop new antibiotics and treatments.

AKTHELIA

  • Grandagarði 16, 101 Reykjavik
  • akthelia@akthelia.is
  • 610502-6440
  • Twitter
© 2023 AKTHELIA